Elvina Almuradova/X
Jun 2, 2025, 17:30
Elvina Almuradova Shares ATOMIC Trial Results Showing Reduced Recurrence in dMMR Colon Cancer
Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology, shared a post on LinkedIn:
“ASCO25 Plenary: ATOMIC trial (A021502)
In stage III dMMR colon cancer, atezolizumab + FOLFOX cut recurrences by 50%
3-yr DFS: 86.4% vs 76.6%
HR: 0.50 | N=700+ | NCI-fundedCould this approach also benefit patients with high-risk stage II colon cancer?
Further studies are definitely needed, but this may open a promising door.”
Read OncoDaily’s Special Articles about ASCO 2025:
15 Posts Not to Miss from the 1st Day of ASCO 2025
15 Posts Not to Miss from the 2nd Day of ASCO 2025
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 22, 2025, 13:38
Jul 22, 2025, 13:21
Jul 22, 2025, 12:56
Jul 22, 2025, 12:42
Jul 22, 2025, 12:15
Jul 22, 2025, 11:56